Mobius Therapeutics, a St. Louis developer of glaucoma treatments, raised $3.5 million in a first funding round, VentureWire reports (subscription required). Individual investors provided the cash.
From the VentureWire story:
Based in St. Louis, [President Ed] Timm founded Mobius last April with a novel device and a reformulation of an already approved drug, trabomycin, which he said has been used off-label for glaucoma surgery for several years. "What we've attempted to do is take an uncontrolled exercise and give it some uniformity," he said. Timm said he hopes to seek 505(b)(2) approval in August from the Food and Drug Administration, which would allow him to bypass clinical trials even though the product is being classed as a drug.